We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+21.42%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
+$5.19M
Cap. Flow
-$8.58M
Cap. Flow %
-8.44%
Top 10 Hldgs %
84.52%
Holding
26
New
3
Increased
2
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$1.53M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$1.01M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$228K
4
ARCT icon
Arcturus Therapeutics
ARCT
+$164K
5
OCRX
Ocera Therapeutics, Inc.
OCRX
+$150K

Top Sells

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$8.33M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$1.21M
3
RGNX icon
Regenxbio
RGNX
+$314K

Sector Composition

Rank Sector Weight
1 Healthcare 68.05%
2 Miscellaneous 31.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$63M
$18.9M 18.57%
1,095,734
– –
CHRS icon
2
Coherus Oncology
CHRS
$226M
$8.18M 8.05%
305,505
-305,505
-50% -$8.33M
AVDL
3
DELISTED
Avadel Pharmaceuticals
AVDL
$6.2M 6.1%
500,000
– –
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$4.53M 4.46%
110,274
– –
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.52B
$4.43M 4.36%
1,005,104
– –
LPCN icon
6
Lipocine
LPCN
$18.4M
$3.79M 3.73%
49,995
– –
CLCD
7
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$2.6M 2.56%
+68,190
New +$1.01M
SIOX
8
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.58M 2.54%
23,014
– –
OCRX
9
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.26M 2.22%
856,550
+60,000
+8% +$150K
LRMR icon
10
Larimar Therapeutics
LRMR
$421M
$1.99M 1.96%
50,176
– –
ASND icon
11
Ascendis Pharma A/S
ASND
$16.4B
$1.81M 1.78%
90,000
– –
ARCT icon
12
Arcturus Therapeutics
ARCT
$460M
$1.63M 1.6%
94,130
+5,085
+6% +$164K
ONC
13
BeOne Medicines Ltd
ONC
$42.1B
$1.57M 1.54%
51,000
– –
STML
14
DELISTED
Stemline Therapeutics, Inc.
STML
$1.47M 1.44%
135,420
– –
ACHN
15
DELISTED
Achillion Pharmaceuticals
ACHN
$1.46M 1.43%
+180,000
New +$1.53M
PDSB icon
16
PDS Biotechnology
PDSB
$12.2M
$1.41M 1.38%
6,750
– –
AKTX
17
Akari Therapeutics
AKTX
$17.5M
$1.35M 1.33%
198
– –
ORKA
18
Oruka Therapeutics
ORKA
$6.39B
$1.31M 1.29%
2,141
– –
CTMX icon
19
CytomX Therapeutics
CTMX
$745M
$1.01M 0.99%
64,200
– –
RGNX icon
20
Regenxbio
RGNX
$619M
$337K 0.33%
24,089
-28,411
-54% -$314K
BOLD
21
DELISTED
Audentes Therapeutics, Inc
BOLD
$267K 0.26%
+15,000
New +$228K
SRRA
22
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$102K 0.1%
1,401
– –
SYRE icon
23
Spyre Therapeutics
SYRE
$8.25B
$38K 0.04%
240
– –
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-72,990
Closed -$1.21M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q3 2016 Portfolio in Review

As of Q3 2016, VHCP Management held 26 positions worth $102M, up 5.4% from $96.5M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

VHCP Management withdrew a net $8.58M in Q3 2016, closing 2 positions and reducing 2 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $1.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 68% a quarter earlier, followed by Miscellaneous.

Against the trend, VHCP Management opened a new position in Achillion Pharmaceuticals worth $1.46M.

  • VHCP Management's largest Q3 2016 buy was Achillion Pharmaceuticals: 180,000 shares worth $1.46M.
  • VHCP Management added most to Arcturus Therapeutics in Q3 2016, an estimated $164K increase.
  • VHCP Management's biggest Q3 2016 reduction was Coherus Oncology, cutting an estimated $8.33M.
  • VHCP Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $1.21M.
  • VHCP Management's ten largest holdings make up 85% of its $102M portfolio in Q3 2016.
  • VHCP Management opened 3 new positions and closed 2 in Q3 2016.
  • VHCP Management's portfolio value rose 5.4% quarter-over-quarter to $102M.

Based on VHCP Management's 13F filing for Q3 2016, filed 14 Nov 2016.